| Monograph Title
|
Monograph Section
|
Scientific Liaison
|
| DILTIAZEM HYDROCHLORIDE ORAL SOLUTION PF 32(1) Pg. 79
|
Title
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SOLUTION PF 32(1) Pg. 79
|
Definition
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SOLUTION PF 32(1) Pg. 79
|
Packaging and storage
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SOLUTION PF 32(1) Pg. 79
|
Labeling
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SOLUTION PF 32(1) Pg. 79
|
USP Reference standards
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SOLUTION PF 32(1) Pg. 79
|
pH
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SOLUTION PF 32(1) Pg. 79
|
Beyond-use date
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SOLUTION PF 32(1) Pg. 79
|
Assay
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 80
|
Title
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 80
|
Definition
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 80
|
Packaging and storage
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 80
|
Labeling
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 80
|
USP Reference standards
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 80
|
pH
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 80
|
Beyond-use date
|
|
| DILTIAZEM HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 80
|
Assay
|
|
| DILUTED ISOSORBIDE MONONITRATE PF 32(6) Pg. 1699
|
USP Reference standards <11>
|
|
| DILUTED ISOSORBIDE MONONITRATE PF 32(6) Pg. 1699
|
Assay
|
|
| DIMETHYL SULFOXIDE GEL PF 33(1) Pg. 52
|
Deliverable volume <698>
|
|
| DIMETHYL SULFOXIDE GEL PF 33(1) Pg. 52
|
Minimum fill <755>
|
|
| DIPYRIDAMOLE ORAL SUSPENSION PF 32(1) Pg. 81
|
Title
|
|
| DIPYRIDAMOLE ORAL SUSPENSION PF 32(1) Pg. 81
|
Definition
|
|
| DIPYRIDAMOLE ORAL SUSPENSION PF 32(1) Pg. 81
|
Packaging and storage
|
|
| DIPYRIDAMOLE ORAL SUSPENSION PF 32(1) Pg. 81
|
Labeling
|
|
| DIPYRIDAMOLE ORAL SUSPENSION PF 32(1) Pg. 81
|
USP Reference standards
|
|
| DIPYRIDAMOLE ORAL SUSPENSION PF 32(1) Pg. 81
|
pH
|
|
| DIPYRIDAMOLE ORAL SUSPENSION PF 32(1) Pg. 81
|
Beyond-use date
|
|
| DIPYRIDAMOLE ORAL SUSPENSION PF 32(1) Pg. 81
|
Assay
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Title
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Chemical structure
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Chemical formula
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Molecular weight
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Chemical names
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
CAS number
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Definition
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Packaging and storage
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
USP Reference standards
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Identification A, B
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Water
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Heavy metals
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Residual solvents
|
|
| DIVALPROEX SODIUM PF 31(5) Pg. 1362
|
Assay
|
|
| DIVALPROEX SODIUM PF 32(6) Pg. 1675
|
Chemical Info
|
|
| DIVALPROEX SODIUM PF 32(6) Pg. 1675
|
Definition
|
|
| DIVALPROEX SODIUM PF 32(6) Pg. 1675
|
Assay
|
|
| DOLASETRON MESYLATE ORAL SOLUTION PF 32(1) Pg. 83
|
Title
|
|
| DOLASETRON MESYLATE ORAL SOLUTION PF 32(1) Pg. 83
|
Definition
|
|
| DOLASETRON MESYLATE ORAL SOLUTION PF 32(1) Pg. 83
|
Packaging and storage
|
|
| DOLASETRON MESYLATE ORAL SOLUTION PF 32(1) Pg. 83
|
Labeling
|
|
| DOLASETRON MESYLATE ORAL SOLUTION PF 32(1) Pg. 83
|
USP Reference standards
|
|
| DOLASETRON MESYLATE ORAL SOLUTION PF 32(1) Pg. 83
|
pH
|
|
| DOLASETRON MESYLATE ORAL SOLUTION PF 32(1) Pg. 83
|
Beyond-use date
|
|
| DOLASETRON MESYLATE ORAL SOLUTION PF 32(1) Pg. 83
|
Assay
|
|
| DOLASETRON MESYLATE ORAL SUSPENSION PF 32(1) Pg. 84
|
Title
|
|
| DOLASETRON MESYLATE ORAL SUSPENSION PF 32(1) Pg. 84
|
Definition
|
|
| DOLASETRON MESYLATE ORAL SUSPENSION PF 32(1) Pg. 84
|
Packaging and storage
|
|
| DOLASETRON MESYLATE ORAL SUSPENSION PF 32(1) Pg. 84
|
Labeling
|
|
| DOLASETRON MESYLATE ORAL SUSPENSION PF 32(1) Pg. 84
|
USP Reference standards
|
|
| DOLASETRON MESYLATE ORAL SUSPENSION PF 32(1) Pg. 84
|
pH
|
|
| DOLASETRON MESYLATE ORAL SUSPENSION PF 32(1) Pg. 84
|
Beyond-use date
|
|
| DOLASETRON MESYLATE ORAL SUSPENSION PF 32(1) Pg. 84
|
Assay
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Title
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Chemical structure
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Molecular formula and weight
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Chemical names and CAS number
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Definition
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Packaging and storage
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
USP Reference standards
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Identification A, B
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Water
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Residue on ignition
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Heavy metals
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Assay
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Loss on drying
|
|
| DOXAZOSIN MESYLATE PF 29(5) Pg. 1470
|
Chromatographic purity
|
|
| DOXAZOSIN MESYLATE PF 32(4) Pg. 1066
|
USP Reference standards <11>
|
|
| DOXAZOSIN MESYLATE PF 32(4) Pg. 1066
|
Loss on drying <731>
|
|
| DOXAZOSIN MESYLATE PF 32(4) Pg. 1066
|
Related compounds
|
|
| DOXAZOSIN MESYLATE PF 32(4) Pg. 1066
|
Assay
|
|
| ESTRADIOL TRANSDERMAL SYSTEM PF 31(4) Pg. 1063
|
Title
|
|
| ESTRADIOL TRANSDERMAL SYSTEM PF 31(4) Pg. 1063
|
Definition
|
|
| ESTRADIOL TRANSDERMAL SYSTEM PF 31(4) Pg. 1063
|
Packaging and storage
|
|
| ESTRADIOL TRANSDERMAL SYSTEM PF 31(4) Pg. 1063
|
Labeling
|
|
| ESTRADIOL TRANSDERMAL SYSTEM PF 31(4) Pg. 1063
|
USP Reference standards
|
|
| ESTRADIOL TRANSDERMAL SYSTEM PF 31(4) Pg. 1063
|
Identification
|
|
| ESTRADIOL TRANSDERMAL SYSTEM PF 31(4) Pg. 1063
|
Uniformity of dosage units
|
|
| ESTRADIOL TRANSDERMAL SYSTEM PF 31(4) Pg. 1063
|
Assay
|
|
| ESTRADIOL TRANSDERMAL SYSTEM PF 31(4) Pg. 1063
|
Alcohol content
|
|
| FAMOTIDINE TABLETS PF 32(6) Pg. 1680
|
Dissolution <711>
|
|
| FINASTERIDE TABLETS PF 32(6) Pg. 1681
|
Dissolution <711>
|
|
| FLUCYTOSINE ORAL SUSPENSION PF 32(1) Pg. 92
|
Title
|
|
| FLUCYTOSINE ORAL SUSPENSION PF 32(1) Pg. 92
|
Definition
|
|
| FLUCYTOSINE ORAL SUSPENSION PF 32(1) Pg. 92
|
Packaging and storage
|
|
| FLUCYTOSINE ORAL SUSPENSION PF 32(1) Pg. 92
|
Labeling
|
|
| FLUCYTOSINE ORAL SUSPENSION PF 32(1) Pg. 92
|
USP Reference standards
|
|
| FLUCYTOSINE ORAL SUSPENSION PF 32(1) Pg. 92
|
pH
|
|
| FLUCYTOSINE ORAL SUSPENSION PF 32(1) Pg. 92
|
Beyond-use date
|
|
| FLUCYTOSINE ORAL SUSPENSION PF 32(1) Pg. 92
|
Assay
|
|
| FLUVASTATIN SODIUM PF 32(6) Pg. 1682
|
Labeling
|
|
| FLUVASTATIN SODIUM PF 32(6) Pg. 1682
|
Identification
|
|
| FLUVASTATIN SODIUM PF 32(6) Pg. 1682
|
Water, Method I <921>
|
|
| FLUVASTATIN SODIUM PF 33(1) Pg. 64
|
Chromatographic purity
|
|
| FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE TABLETS PF 33(1) Pg. 66
|
USP Reference standards <11>
|
|
| FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE TABLETS PF 33(1) Pg. 66
|
Identification
|
|
| FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE TABLETS PF 33(1) Pg. 66
|
Related compounds
|
|
| FOSINOPRIL SODIUM PF 32(6) Pg. 1686
|
Related compounds
|
|
| FOSINOPRIL SODIUM PF 32(6) Pg. 1686
|
Residual solvents <467>
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Title
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Chemical Info
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Definition
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Packaging and storage
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Identification
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Acid value <401>
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Iodine value <401>
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Peroxide value <401>
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Unsaponifiable matter <401>
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Fatty acid composition
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Residue on ignition <281>
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Heavy metals, Method II <231>
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Limit of erucic acid
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Alkaline impurities
|
|
| FULLY HYDROGENATED RAPESEED OIL PF 32(6) Pg. 1771
|
Limit of nickel
|
|
| GABAPENTIN CAPSULES PF 32(6) Pg. 1693
|
Title
|
|
| GABAPENTIN CAPSULES PF 32(6) Pg. 1693
|
Definition
|
|
| GABAPENTIN CAPSULES PF 32(6) Pg. 1693
|
Packaging and storage
|
|
| GABAPENTIN CAPSULES PF 32(6) Pg. 1693
|
USP Reference standards <11>
|
|
| GABAPENTIN CAPSULES PF 32(6) Pg. 1693
|
Identification
|
|
| GABAPENTIN CAPSULES PF 32(6) Pg. 1693
|
Dissolution <711>
|
|
| GABAPENTIN CAPSULES PF 32(6) Pg. 1693
|
Uniformity of dosage units <905>
|
|
| GABAPENTIN CAPSULES PF 32(6) Pg. 1693
|
Related compounds
|
|
| GABAPENTIN CAPSULES PF 32(6) Pg. 1693
|
Assay
|
|
| GABAPENTIN PF 31(1) Pg. 50
|
Labeling
|
|
| GABAPENTIN PF 31(1) Pg. 50
|
Related compounds
|
|
| GABAPENTIN PF 32(6) Pg. 1689
|
Labeling
|
|
| GABAPENTIN PF 32(6) Pg. 1689
|
Limit of chloride
|
|
| GABAPENTIN PF 32(6) Pg. 1689
|
Related compounds
|
|
| GABAPENTIN PF 32(6) Pg. 1689
|
Assay
|
|
| GABAPENTIN TABLETS PF 32(6) Pg. 1695
|
Title
|
|
| GABAPENTIN TABLETS PF 32(6) Pg. 1695
|
Definition
|
|
| GABAPENTIN TABLETS PF 32(6) Pg. 1695
|
Packaging and storage
|
|
| GABAPENTIN TABLETS PF 32(6) Pg. 1695
|
USP Reference standards <11>
|
|
| GABAPENTIN TABLETS PF 32(6) Pg. 1695
|
Identification
|
|
| GABAPENTIN TABLETS PF 32(6) Pg. 1695
|
Dissolution <711>
|
|
| GABAPENTIN TABLETS PF 32(6) Pg. 1695
|
Uniformity of dosage units <905>
|
|
| GABAPENTIN TABLETS PF 32(6) Pg. 1695
|
Related compounds
|
|
| GABAPENTIN TABLETS PF 32(6) Pg. 1695
|
Assay
|
|
| GANCICLOVIR ORAL SUSPENSION PF 32(1) Pg. 113
|
Title
|
|
| GANCICLOVIR ORAL SUSPENSION PF 32(1) Pg. 113
|
Definition
|
|
| GANCICLOVIR ORAL SUSPENSION PF 32(1) Pg. 113
|
Packaging and storage
|
|
| GANCICLOVIR ORAL SUSPENSION PF 32(1) Pg. 113
|
Labeling
|
|
| GANCICLOVIR ORAL SUSPENSION PF 32(1) Pg. 113
|
USP Reference standards
|
|
| GANCICLOVIR ORAL SUSPENSION PF 32(1) Pg. 113
|
pH
|
|
| GANCICLOVIR ORAL SUSPENSION PF 32(1) Pg. 113
|
Beyond-use date
|
|
| GANCICLOVIR ORAL SUSPENSION PF 32(1) Pg. 113
|
Assay
|
|
| HYDROCORTISONE TABLETS PF 33(1) Pg. 72
|
Dissolution <711>
|
|
| IMIPENEM AND CILASTATIN FOR INJECTABLE SUSPENSION PF 32(6) Pg. 1698
|
Uniformity of dosage units <905>
|
|
| IMIPENEM AND CILASTATIN FOR INJECTION PF 32(6) Pg. 1698
|
Uniformity of dosage units <905>
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 31(4) Pg. 1082
|
Title
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 31(4) Pg. 1082
|
Definition
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 31(4) Pg. 1082
|
Packaging and storage
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 31(4) Pg. 1082
|
Labeling
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 31(4) Pg. 1082
|
USP Reference standards
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 31(4) Pg. 1082
|
Identification A, B
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 31(4) Pg. 1082
|
Uniformity of dosage units
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 31(4) Pg. 1082
|
Related compounds
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 31(4) Pg. 1082
|
Assay
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 32(6) Pg. 1703
|
USP Reference standards <11>
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 32(6) Pg. 1703
|
Dissolution <711>
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 32(6) Pg. 1703
|
Related compounds
|
|
| ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS PF 32(6) Pg. 1703
|
Assay
|
|
| LABETALOL HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 117
|
Title
|
|
| LABETALOL HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 117
|
Definition
|
|
| LABETALOL HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 117
|
Packaging and storage
|
|
| LABETALOL HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 117
|
Labeling
|
|
| LABETALOL HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 117
|
USP Reference standards
|
|
| LABETALOL HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 117
|
pH
|
|
| LABETALOL HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 117
|
Beyond-use date
|
|
| LABETALOL HYDROCHLORIDE ORAL SUSPENSION PF 32(1) Pg. 117
|
Assay
|
|
| LACTULOSE CONCENTRATE PF 32(6) Pg. 1709
|
Related compounds
|
|
| LACTULOSE CONCENTRATE PF 32(6) Pg. 1709
|
Assay
|
|
| LANSOPRAZOLE PF 32(6) Pg. 1710
|
Definition
|
|
| LANSOPRAZOLE PF 32(6) Pg. 1710
|
Water, Method Ia <921>
|
|
| LANSOPRAZOLE PF 32(6) Pg. 1710
|
Residue on ignition <281>
|
|
| LANSOPRAZOLE PF 32(6) Pg. 1710
|
Chromatographic purity
|
|
| LANSOPRAZOLE PF 32(6) Pg. 1710
|
Assay
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Title
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Chemical structure
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Chemical formula
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Molecular weight
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Chemical names
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
CAS number
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Definition
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Packaging and storage
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
USP Reference standards
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Identification A, B
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Loss on drying
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Residue on ignition
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Heavy metals
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Limit of leflunomide related compound A
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Organic volatile impurities
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Residual solvents
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Assay
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Melting range
|
|
| LEFLUNOMIDE PF 31(5) Pg. 1380
|
Chromatographic purity
|
|
| LEFLUNOMIDE TABLETS PF 31(5) Pg. 1383
|
Title
|
|
| LEFLUNOMIDE TABLETS PF 31(5) Pg. 1383
|
Definition
|
|
| LEFLUNOMIDE TABLETS PF 31(5) Pg. 1383
|
Packaging and storage
|
|
| LEFLUNOMIDE TABLETS PF 31(5) Pg. 1383
|
USP Reference standards
|
|
| LEFLUNOMIDE TABLETS PF 31(5) Pg. 1383
|
Identification A, B
|
|
| LEFLUNOMIDE TABLETS PF 31(5) Pg. 1383
|
Uniformity of dosage units
|
|
| LEFLUNOMIDE TABLETS PF 31(5) Pg. 1383
|
Water
|
|
| LEFLUNOMIDE TABLETS PF 31(5) Pg. 1383
|
Assay
|
|
| LEFLUNOMIDE TABLETS PF 31(5) Pg. 1383
|
Related compounds
|
|
| LEFLUNOMIDE TABLETS PF 32(6) Pg. 1712
|
Dissolution <711>
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Title
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Chemical structure
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Chemical formula
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Chemical names
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Cas number
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Definition
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Packaging and storage
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
USP Reference standards
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Identification A, B, C
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Specific rotation
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Loss on drying
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Residue on ignition
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Related compounds
|
|
| LEVOCABASTINE HYDROCHLORIDE PF 31(6) Pg. 1647
|
Assay
|
|
| MAGNESIUM CARBONATE PF 32(6) Pg. 1719
|
Limit of calcium
|
|
| MAGNESIUM CARBONATE PF 32(6) Pg. 1719
|
Assay
|
|
| MAGNESIUM CHLORIDE PF 32(6) Pg. 1720
|
Limit of calcium
|
|
| MAGNESIUM OXIDE PF 32(6) Pg. 1720
|
Limit of calcium
|
|
| MAGNESIUM OXIDE PF 32(6) Pg. 1720
|
Assay
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
Title
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
Definition
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
Packaging and storage
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
USP Reference standards <11>
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
Identification
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
pH <791>
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
Viscosity <911>
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
Dissolution <711>
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
Microbial limits <61>
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
Chromatographic purity
|
|
| MELOXICAM ORAL SUSPENSION PF 32(6) Pg. 1721
|
Assay
|
|
| MELOXICAM TABLETS PF 32(5) Pg. 1460
|
Dissolution <711>
|
|
| MEROPENEM FOR INJECTION PF 32(6) Pg. 1724
|
Assay
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(3) Pg. 772
|
Title
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(3) Pg. 772
|
Definition
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(3) Pg. 772
|
Packaging and storage
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(3) Pg. 772
|
Labeling
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(3) Pg. 772
|
USP Reference standards
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(3) Pg. 772
|
Identification
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(3) Pg. 772
|
Uniformity of dosage units
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(3) Pg. 772
|
Chromatographic purity
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(3) Pg. 772
|
Assay
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 31(3) Pg. 772
|
Dissolution
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 32(6) Pg. 1726
|
Dissolution <711>
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 32(6) Pg. 1726
|
Dissolution <711>
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 32(6) Pg. 1726
|
Chromatographic purity
|
|
| METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PF 32(6) Pg. 1726
|
Assay
|
|
| METOLAZONE ORAL SUSPENSION PF 32(1) Pg. 119
|
Title
|
|
| METOLAZONE ORAL SUSPENSION PF 32(1) Pg. 119
|
Definition
|
|
| METOLAZONE ORAL SUSPENSION PF 32(1) Pg. 119
|
Packaging and storage
|
|
| METOLAZONE ORAL SUSPENSION PF 32(1) Pg. 119
|
Labeling
|
|
| METOLAZONE ORAL SUSPENSION PF 32(1) Pg. 119
|
USP Reference standards
|
|
| METOLAZONE ORAL SUSPENSION PF 32(1) Pg. 119
|
pH
|
|
| METOLAZONE ORAL SUSPENSION PF 32(1) Pg. 119
|
Beyond-use date
|
|
| METOLAZONE ORAL SUSPENSION PF 32(1) Pg. 119
|
Assay
|
|
| METOPROLOL TARTRATE ORAL SOLUTION PF 32(1) Pg. 121
|
Title
|
|
| METOPROLOL TARTRATE ORAL SOLUTION PF 32(1) Pg. 121
|
Definition
|
|
| METOPROLOL TARTRATE ORAL SOLUTION PF 32(1) Pg. 121
|
Packaging and storage
|
|
| METOPROLOL TARTRATE ORAL SOLUTION PF 32(1) Pg. 121
|
Labeling
|
|
| METOPROLOL TARTRATE ORAL SOLUTION PF 32(1) Pg. 121
|
USP Reference standards
|
|
| METOPROLOL TARTRATE ORAL SOLUTION PF 32(1) Pg. 121
|
pH
|
|
| METOPROLOL TARTRATE ORAL SOLUTION PF 32(1) Pg. 121
|
Beyond-use date
|
|
| METOPROLOL TARTRATE ORAL SOLUTION PF 32(1) Pg. 121
|
Assay
|
|
| METOPROLOL TARTRATE ORAL SUSPENSION PF 32(1) Pg. 122
|
Title
|
|
| METOPROLOL TARTRATE ORAL SUSPENSION PF 32(1) Pg. 122
|
Definition
|
|
| METOPROLOL TARTRATE ORAL SUSPENSION PF 32(1) Pg. 122
|
Packaging and storage
|
|
| METOPROLOL TARTRATE ORAL SUSPENSION PF 32(1) Pg. 122
|
Labeling
|
|
| METOPROLOL TARTRATE ORAL SUSPENSION PF 32(1) Pg. 122
|
USP Reference standards
|
|
| METOPROLOL TARTRATE ORAL SUSPENSION PF 32(1) Pg. 122
|
pH
|
|
| METOPROLOL TARTRATE ORAL SUSPENSION PF 32(1) Pg. 122
|
Beyond-use date
|
|
| METOPROLOL TARTRATE ORAL SUSPENSION PF 32(1) Pg. 122
|
Assay
|
|
| MORANTEL TARTRATE PF 32(6) Pg. 1735
|
Definition
|
|
| MORANTEL TARTRATE PF 32(6) Pg. 1735
|
Related compounds
|
|
| NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS PF 33(1) Pg. 81
|
Dissolution <711>
|
|
